SCHEMBL32674300

SCHEMBL32674300

COc1ccc(Cn2c(=O)oc3ccc(Cc4nn[nH]n4)c(F)c32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 1/20 0.42
▸ ALDH1A1 P00352 6/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ HPGD P15428 4/20 0.38
▸ HSD17B10 Q99714 4/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAPT P10636 4/20 0.36
▸ PIK3R1 P27986 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ CYSLTR2 Q9NS75 1/20 0.36
▸ CYSLTR1 Q9Y271 1/20 0.36
▸ CD74 P04233 1/20 0.36
▸ MIF P14174 1/20 0.36
▸ KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32674502 0.79 MAPT (0.36) ALDH1A1KDM4EHPGDTP53POLB
SCHEMBL32674486 0.77 ALDH1A1 (0.41) ALDH1A1KDM4EPOLBMAPTCD74
SCHEMBL32674374 0.77 KMO (0.45) PLA2G2AALDH1A1KDM4EMAPTCD74
SCHEMBL32674120 0.76 MIF (0.41) PLA2G2AALDH1A1CD74MIFKMT2A
SCHEMBL32674271 0.67 MAPT (0.47) ALDH1A1TP53MAPTCD74MIF
SCHEMBL32674408 0.67 LMNA (0.45) ALDH1A1KDM4EPOLBMAPTCD74
SCHEMBL31667649 0.67 KMT2A (0.48) ALDH1A1KDM4ETP53POLBMAPT
SCHEMBL16099478 0.66 POLB (0.51) ALDH1A1KDM4EHPGDTP53POLB
SCHEMBL18805695 0.66 IDO1 (0.72) ALDH1A1POLBCD74MIFKMT2A
SCHEMBL31667303 0.65 POLB (0.42) ALDH1A1KDM4EPOLBMAPTCD74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof TRIANA BIOMEDICINES, INC. (US) 2026-03-03 — — US disclosed
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2026-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042752-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF ALK, NTRK1, NTRK3 PLA2G2A 4583/4885ALDH1A1 2403/4885KDM4E 1241/4885
US-12565492-B2 Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof ALK, NTRK3, NTRK1 PLA2G2A 4290/4885ALDH1A1 2387/4885KDM4E 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback